Premium
Reviving pegylated interferon as a therapeutic agent for hepatitis D: No more room for nucleos(t)ides?
Author(s) -
Lutz Holger H.,
Trautwein Christian
Publication year - 2011
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.24311
Subject(s) - adefovir , medicine , gastroenterology , hbsag , placebo , pegylated interferon , hepatitis d virus , peginterferon alfa 2a , ribavirin , chronic hepatitis , virology , hepatitis b virus , virus , lamivudine , pathology , alternative medicine
Chronic infection with hepatitis B virus and hepatitis delta virus (HDV) results in the most severe form of viral hepatitis. There is no currently approved treatment. We investigated the safety and efficacy of 48 weeks of treatment with peginterferon alfa-2a plus adefovir dipivoxil, peginterferon alfa-2a alone,and adefovir dipivoxil alone.